Literature DB >> 10693862

Approaches for identifying and defining environmentally associated rheumatic disorders.

F W Miller1, E V Hess, D J Clauw, P A Hertzman, T Pincus, R M Silver, M D Mayes, J Varga, T A Medsger, L A Love.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10693862     DOI： 10.1002/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  15 in total

1.  A case of anti-Jo1 myositis with pleural effusions and pericardial tamponade developing after exposure to a fermented Kombucha beverage.

Authors:  Chris T Derk; Nora Sandorfi; Mark T Curtis
Journal:  Clin Rheumatol       Date:  2004-04-16       Impact factor: 2.980

2.  Acrylamine-induced autoimmune phenomena.

Authors:  Bruce Rothschild
Journal:  Clin Rheumatol       Date:  2010-06-11       Impact factor: 2.980

3.  Guillain-Barré syndrome after short-course efalizumab treatment.

Authors:  Marco Turatti; Stefano Tamburin; Domenico Idone; Maria Luigia Praitano; Giampietro Zanette
Journal:  J Neurol       Date:  2010-03-27       Impact factor: 4.849

4.  Criteria for environmentally associated autoimmune diseases.

Authors:  Frederick W Miller; K Michael Pollard; Christine G Parks; Dori R Germolec; Patrick S C Leung; Carlo Selmi; Michael C Humble; Noel R Rose
Journal:  J Autoimmun       Date:  2012-07-06       Impact factor: 7.094

5.  Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis.

Authors:  L M Amezcua-Guerra; B Hernández-Martínez; C Pineda; R Bojalil
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

6.  Occupational exposure in patients with the antisynthetase syndrome.

Authors:  Ane Labirua-Iturburu; Albert Selva-O'Callaghan; Jan-Paul Zock; Ramon Orriols; Xavier Martínez-Gómez; Miquel Vilardell-Tarrés
Journal:  Clin Rheumatol       Date:  2014-01-03       Impact factor: 2.980

Review 7.  Monoclonal antibody therapy-associated neurological disorders.

Authors:  Xavier Bosch; Albert Saiz; Manuel Ramos-Casals
Journal:  Nat Rev Neurol       Date:  2011-01-25       Impact factor: 42.937

Review 8.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

9.  Prescription medication use and antinuclear antibodies in the United States, 1999-2004.

Authors:  Gregg E Dinse; Christine G Parks; Helen C S Meier; Caroll A Co; Edward K L Chan; Todd A Jusko; James Yeh; Frederick W Miller
Journal:  J Autoimmun       Date:  2018-05-18       Impact factor: 7.094

Review 10.  Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review.

Authors:  Bonifacio Alvarez-Lario; Rosa Prieto-Tejedo; María Colazo-Burlato; Jesús Macarrón-Vicente
Journal:  Clin Rheumatol       Date:  2013-05-11       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.